Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

13 Mar 2024 13:00:00 By Nasdaq GlobeNewswire

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

07 Mar 2024 12:00:00 By Nasdaq GlobeNewswire

Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up

05 Mar 2024 12:00:00 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

04 Mar 2024 12:00:00 By Nasdaq GlobeNewswire

Oxurion Announces New Strategic Orientation to De-risk and Diversify

22 Jan 2024 15:02:36 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

19 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

17 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

12 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas

28 Dec 2023 14:15:00 By Nasdaq GlobeNewswire

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

01 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

20 Nov 2023 00:00:00 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

19 Nov 2023 14:00:00 By Nasdaq GlobeNewswire

Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year

16 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

16 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

15 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

06 Nov 2023 13:00:00 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

03 Nov 2023 14:00:00 By Nasdaq GlobeNewswire

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

30 Oct 2023 02:00:00 By Nasdaq GlobeNewswire

Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial

25 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

20 Oct 2023 13:01:00 By Nasdaq GlobeNewswire